Tumour Regression Induced by Co-administration of MIP-3α and CpG in an Experimental Model of Colon Carcinoma


Correspondence to: J. Hadjati, Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Poursina Avenue, Keshavarz Blvd, Tehran 1417613151, Iran.

E-mail: hajatij@sina.tums.ac.ir


CCL20/macrophage inflammatory protein-3α (MIP-3α) represents one of the potent chemoattractive proteins for dendritic cells (DCs). Herein, we investigated whether in vivo genetic modification of tumour cells aimed at intratumoural production of MIP-3α might lead to accumulation of DCs in tumour tissue. Mice injected with CT26, received recombinant adenovirus (Ad) vectors (AdMIP-3α) expressing MIP-3α protein. This was complemented by injections of CpG. Interestingly, MIP-3α gene therapy combined with CpG injections resulted in specific cytotoxicity. This was associated with significant suppression of tumour growth rate. These findings demonstrate the potential of strategies that utilize in vivo overexpression of chemokines.